Moderna, Inc. (MRNA) P/E Ratio History
Deep ValueTrading at -26.2x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2021–2023
Loading P/E history...
P/E Ratio Analysis
As of October 3, 2026, Moderna, Inc. (MRNA) trades at a price-to-earnings ratio of -26.2x, with a stock price of $190.01 and trailing twelve-month earnings per share of $-7.96.
The current P/E is 206% below its 5-year average of 24.7x. Over the past five years, MRNA's P/E has ranged from a low of 4.3x to a high of 104.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, MRNA trades at a 213% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, MRNA trades at a notable discount to the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MRNA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MRNA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MRNA P/E vs Peers
Vaccines and Infectious Disease peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 4.1Lowest | - | +307% | |
| $1B | 6.5 | - | +161% | |
| $158B | 20.4 | - | -4% | |
| $616B | 23.2 | 1.56 | +91% | |
| $122B | 12.0 | 0.55 | +45% | |
| $180B | 21.3 | 0.16Best | +1684%Best | |
| $76B | 17.7 | 2.80 | +8% | |
| $128B | 32.9 | 3.98 | +837% | |
| $243B | 36.9 | 17.48 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MRNA Historical P/E Data (2021–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q2 | Jun 30 2023 | $121.50 | $2.73 | 44.5x | +80% |
| FY2023 Q1 | Mar 31 2023 | $153.58 | $11.59 | 13.3x | -46% |
| FY2022 Q4 | Dec 31 2022 | $179.62 | $19.97 | 9.0x | -64% |
| FY2022 Q3 | Sep 30 2022 | $118.25 | $27.64 | 4.3x | -83% |
| FY2022 Q2 | - | $142.85 | $32.81 | 4.4x | -82% |
| FY2022 Q1 | - | $172.26 | $34.03 | 5.1x | -80% |
| FY2021 Q4 | Dec 31 2021 | $253.98 | $28.29 | 9.0x | -64% |
| FY2021 Q3 | - | $384.86 | $16.31 | 23.6x | -4% |
| FY2021 Q2 | Jun 30 2021 | $234.98 | $8.02 | 29.3x | +19% |
| FY2021 Q1 | Mar 31 2021 | $130.95 | $1.25 | 104.8x | +324% |
Average P/E for displayed period: 24.7x
MRNA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MRNA — Frequently Asked Questions
Quick answers to the most common questions about buying MRNA stock.
What is MRNA's P/E ratio?
Moderna, Inc. (MRNA) trailing twelve-month P/E ratio is -26.2x, based on TTM diluted EPS of $-7.96. The 5-year average P/E is 24.7x and the historical range spans 4.3x to 104.8x.
Is MRNA stock overvalued or undervalued?
MRNA trades at -26.2x P/E, below its 5-year average of 24.7x. At the 0th percentile of its historical range (4.3x–104.8x), the stock is priced at a discount to its own history.
Is MRNA stock expensive?
No, MRNA is not expensive on a historical basis. The current P/E of -26.2x is below the 5-year average of 24.7x and sits at the 0th percentile of its valuation range.
What is MRNA's historical P/E range?
Over the past 5 years, MRNA's P/E ratio has ranged from 4.3x to 104.8x, with a median of 13.3x and an average of 24.7x. The current P/E of -26.2x places the stock at the 0th percentile of this range. Full historical data spans 2021–2023.
How does MRNA's P/E compare to the S&P 500?
MRNA trades at -26.2x P/E versus the S&P 500 median of 24.5x. The 207% discount to the market suggests lower growth expectations or perceived higher risk.
How does MRNA's valuation compare to Healthcare peers?
Moderna, Inc. P/E of -26.2x compares to the Healthcare sector median of 23.2x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is MRNA's PEG ratio?
MRNA PEG ratio is N/A, based on a P/E of -26.2x and EPS growth of 21.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is MRNA's earnings yield?
MRNA earnings yield is N/A, the inverse of its -26.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.